BEST of ASCO Portugal 2024 - IG
BEST of ASCO Portugal 2024
Abstract
The treatment of lung cancer has evolved significantly in recent years, mainly due to the development of immunotherapy and molecular-targeted therapies. As with advanced disease, important advances have also been made in localized disease, which have resulted in changes in the treatment paradigm in this disease context. This article analyzes the main studies presented at the 2024 annual congress of the American Society of Clinical Oncology in the field of localized lung cancer and mesothelioma.
Downloads
References
Rebecca L Siegel, Kimberly D Miller, Nikita Sandeep Wagle, Ahmedin Jemal. Cancer statistics, 2023. CA Cancer J. Clin. 2023, 73, 17-48.
Megan E Daly, Navneet Singh, et al. Management of Stage III Non-Small-Cell Lung Cancer: ASCO Guideline. J Clin Oncol. 2022 Apr 20;40(12):1356-1384.
Scott J Antonia, Augusto Villegas, et al; PACIFIC Investigators. Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. N Engl J Med. 2017 Nov 16;377(20):1919-1929.
Scott J Antonia, Augusto Villegas, et al; PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018 Dec 13;379(24):2342-2350.
Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E E Eberhardt, Andrew G Nicholson, Patti Groome , Alan Mitchell, Vanessa Bolejack; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions; International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Jan;11(1):39-51.
Jean-Pierre Pignon, Hélène Tribodet, et al; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008 Jul 20;26(21):3552-9.
NSCLC Meta-analysis Collaborative Group. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014 May 3;383(9928):1561-71.
Antonio Nuccio, Giuseppe Viscardi, et al. Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies. Eur J Cancer. 2023 Dec:195:113404.
Tina Cascone, Mark M Awad, et al.; CheckMate 77T Investigators. Perioperative Nivolumab in Resectable Lung Cancer. N Engl J Med. 2024 May 16;390(19):1756-1769.
Spicer JD, Gao S, Liberman M, et al. LBA56 Overall survival in the KEYNOTE-671 study of perioperative pembrolizumab for early-stge non-small-cell lung cancer (NSCLC). Ann Oncol 2023;34:Suppl 2:S1297-S1298 (https://www.annalsofoncology.org/article/S0923-7534(23)04196-0/fulltext).
Heymach JV, HarpoleD, Mitsudomi T, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med 2023;389:1672-84.
Lu S, Chang W, Wu L, et al. Perioperative toripalimab plus chemotherapy for patients with resectable non-small cell lung cancer: the Neotorch randomized clinical trial. JAMA 2024;331:201-11.
D. Yue, W. Wang, H. Liu, et al. VP1-2024: RATIONALE-315: Event-free survival (EFS) and overall survival (OS) of neoadjuvant tislelizumab (TIS) plus chemotherapy (CT) with adjuvant TIS in resectable non-small cell lung cancer (NSCLC) (RATIONALE 315). Ann Oncol 2024;35:332-3 (https://www.annalsofoncology.org/article/S0923-7534(24)00012-7/fulltext).
Wen-Yu Zhai, Ze-Rui Zhao, Si Chen, et al. Response of primary tumor and lymph node in non-small cell lung cancer after neoadjuvant immunotherapy: a pooled analysis. J Immunother Cancer. 2022 Sep;10(9):e005160.
Jarushka Naidoo, Scott Antonia, et al. Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC. J Thorac Oncol. 2023 May;18(5):657-663.
Shun Lu , Terufumi Kato, Xiaorong Dong, et al. Osimertinib after Chemoradiotherapy in Stage III EGFR-Mutated NSCLC. N Engl J Med. 2024 Aug 15;391(7):585-597.
Roy S. Herbst, Yi-Long Wu, Thomas John, et al. Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023 Apr 1; 41(10): 1830–1840.
Jon Zugazagoitia, Luis Paz-Ares. Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options. J Clin Oncol. 2022 Feb 20;40(6):671-680.
Corinne Faivre-Finn , Michael Snee, et al.; CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017 Aug;18(8):1116-1125.
Jeffrey Bogart, Xiaofei Wang, et al. High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. J Clin Oncol. 2023 May 1;41(13):2394-2402.
Luis Paz-Ares, Mikhail Dvorkin, et al.; CASPIAN investigators. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019 Nov 23;394(10212):1929-1939.
Horn L, Mansfield AS, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018;379(23):2220.
Paul Baas, Arnaud Scherpereel, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021 Jan 30;397(10272):375-386.
Quincy Chu, Francesco Perrone, et al. Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial. Lancet. 2023 Dec 16;402(10419):2295-2306.
Gérard Zalcman, Julien Mazieres, et al.; French Cooperative Thoracic Intergroup (IFCT). Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016 Apr 2;387(10026):1405-1414.
Ryota Tamura, Toshihide Tanaka, et al. The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications. Med Oncol. 2019 Nov 11;37(1):2.
